untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2018-01-15T18:33:03Z</responseDate>
<request identifier=oai:HAL:hal-00875434v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:hal-00875434v1</identifier>
<datestamp>2017-12-21</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>collection:UPMC</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
<setSpec>collection:IFR140</setSpec>
<setSpec>collection:UNIV-RENNES1</setSpec>
<setSpec>collection:IRSET</setSpec>
<setSpec>collection:APHP</setSpec>
<setSpec>collection:IRSET-HIAEC</setSpec>
<setSpec>collection:BIOSIT</setSpec>
<setSpec>collection:ANRSCO4</setSpec>
<setSpec>collection:UR1-UFR-SVE</setSpec>
<setSpec>collection:STATS-UR1</setSpec>
<setSpec>collection:UR1-HAL</setSpec>
<setSpec>collection:EHESP</setSpec>
<setSpec>collection:USPC</setSpec>
<setSpec>collection:UR1-SDV</setSpec>
<setSpec>collection:IRSET-2</setSpec>
<setSpec>collection:UNIV-ANGERS</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=en>Survival after neuroAIDS: association with antiretroviral CNS Penetration-Effectiveness score.</title>
<creator>Lanoy, Emilie</creator>
<creator>Guiguet, Marguerite</creator>
<creator>Bentata, M.</creator>
<creator>Rouveix, Elisabeth</creator>
<creator>Dhiver, C.</creator>
<creator>Poizot-Martin, Isabelle</creator>
<creator>Costagliola, Dominique</creator>
<creator>Gasnault, J.</creator>
<creator>Michelet, Christian</creator>
<contributor>Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH ; Université Pierre et Marie Curie - Paris 6 (UPMC) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Service de Médecine Interne ; Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Ambroise Paré</contributor>
<contributor>Département de Recherche CLinique ; CISIH-Sud, Hôpital Sainte-Marguerite</contributor>
<contributor>Institut de recherche, santé, environnement et travail [Rennes] (Irset) ; Université d'Angers (UA) - Université des Antilles et de la Guyane (UAG) - Université de Rennes 1 (UR1) - École des Hautes Études en Santé Publique [EHESP] (EHESP) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )</contributor>
<description>International audience</description>
<source>ISSN: 0028-3878</source>
<source>EISSN: 1526-632X</source>
<source>Neurology</source>
<publisher>American Academy of Neurology</publisher>
<identifier>hal-00875434</identifier>
<identifier>https://hal.archives-ouvertes.fr/hal-00875434</identifier>
<source>https://hal.archives-ouvertes.fr/hal-00875434</source>
<source>Neurology, American Academy of Neurology, 2011, 76 (7), pp.644-51. 〈10.1212/WNL.0b013e31820c3089〉</source>
<identifier>DOI : 10.1212/WNL.0b013e31820c3089</identifier>
<relation>info:eu-repo/semantics/altIdentifier/doi/10.1212/WNL.0b013e31820c3089</relation>
<identifier>PUBMED : 21248274</identifier>
<relation>info:eu-repo/semantics/altIdentifier/pmid/21248274</relation>
<language>en</language>
<subject>[SDV.IMM] Life Sciences [q-bio]/Immunology</subject>
<subject>[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases</subject>
<type>info:eu-repo/semantics/article</type>
<type>Journal articles</type>
<description lang=en>OBJECTIVE: We examined if the CNS Penetration-Effectiveness (CPE) score of antiretroviral drugs was associated with survival after a diagnosis of HIV-related encephalopathy, progressive multifocal leukoencephalopathy (PML), cerebral toxoplasmosis, or cryptococcal meningitis. METHODS: Using data from the FHDH-ANRS CO4, we compared the survival of 9,932 HIV-infected patients diagnosed with a first neurologic AIDS-defining event in the pre-combination antiretroviral therapy (cART) (1992-1995), early cART (1996-1998), or late cART (1999-2004) periods. Follow-up was subdivided (CPE < 1.5 and CPE ≥ 1.5), and relative rates (RR) of death were estimated using multivariable Poisson regression models. RESULTS: In the pre-cART and early cART periods, regimens with CPE ≥ 1.5 were associated with lower mortality after HIV-related encephalopathy (RR 0.64; 95% confidence interval [CI] 0.47-0.86 and RR 0.45; 95% CI 0.35-0.58) and after PML (RR 0.79; 95% CI 0.55-1.12 and RR 0.45; 95% CI 0.31-0.65), compared to regimens with CPE < 1.5, while in the late cART period there was no association between the CPE score and the mortality. A higher CPE score was also associated with a lower mortality in all periods after cerebral toxoplasmosis (RR 0.68, 95% CI 0.56-0.84) or cryptococcal meningitis (RR 0.50, 95% CI 0.34-0.74). Whatever the neurologic event, these associations were not maintained after adjustment on updated plasma HIV-RNA (missing, <500, ≥500 copies/mL) with RR ranging from 0.82 (95% CI 0.36-1.91) to 1.02 (0.69-1.52). CONCLUSION: At the beginning of the cART era, the CPE score was of importance for survival after severe neurologic event, while in the late cART period, the additional effect of CPE score vanished with more powerful antiretroviral regimens associated with plasma viral load control.</description>
<contributor>FHDH-ANRS CO4</contributor>
<date>2011-02-15</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>
